Cancer is the most complex genetic disease known, with mutations implicated in more than 250 genes. However, it is still elusive which specific mutations found in human patients lead to tumorigenesis. Here we show that a combination of oncogenes that is characteristic of liver cancer (CTNNB1, TERT, MYC) induces senescence in human fibroblasts and primary hepatocytes. However, reprogramming fibroblasts to a liver progenitor fate, induced hepatocytes (iHeps), makes them sensitive to transformation by the same oncogenes. The transformed iHeps are highly proliferative, tumorigenic in nude mice, and bear gene expression signatures of liver cancer. These results show that tumorigenesis is triggered by a combination of three elements: the set of driver mutations, the cellular lineage, and the state of differentiation of the cells along the lineage. Our results indicate that cell identity is a key determinant in transformation, and establish a paradigm for defining the molecular states of human cancer.
. Transdifferentiation of fibroblasts to iHeps has previously been reported by several groups (Du et al., 2014; Huang et al., 2014; Morris et al., 2014; Sekiya and Suzuki, 2011) . To identify an optimal protocol for generating iHeps from HFs (from human foreskin), we tested the previously reported combinations of TFs in parallel transdifferentiation experiments and analyzed the efficiency of iHep conversion by measuring the mRNA levels for liver markers (Du et al., 2014; Huang et al., 2014; Morris et al., 2014) such as ALBUMIN, TRANSFERRIN, and SERPINA1 at different time points (Figure 1B, Figure S1 ). The combination of three TFs, HNF1A, HNF4A and FOXA3 (Huang et al., 2014) resulted in the most efficient iHep generation, based on the observation that out of all combinations tested, this combination resulted in the highest expression level of liver-specific genes at two, three, and four weeks after iHep induction (Figure 1B) . This protocol also resulted in most efficient lineage conversion based on the analysis of cell morphology; by two weeks after iHep induction, the cells lost their fibroblast phenotype and formed spherical iHep progenitor colonies, from which immature, proliferative iHeps migrated outward. The iHeps fully matured to non-proliferative iHeps by six to seven weeks after induction (Figure 2A, Figure   S2 ).
Oncogene exposure transforms induced hepatocytes but not control fibroblasts
To determine whether the iHeps could be transformed to liver cancer-like cells, we first plated immature (1 to 3 weeks post-transdifferentiation) iHeps on collagen-coated dishes and maintained them in hepatocyte culture media (HCM) . Under such conditions, the iHeps mature, and their proliferation is arrested after two to three passages (Huang et al., 2014) ; after this point, further passaging induces cell death (Figure 2B) . To confer the immature iHeps with unlimited proliferative potential and to drive them towards tumorigenesis, we transduced them with a set of the most common driver genes for liver cancer using lentiviral 5 constructs. For this purpose, we chose the five oncogenic drivers with the highest number of recurrent genetic alterations reported for liver cancer or hepatocellular carcinoma (HCC; from COSMIC, https://cancer.sanger.ac.uk/cosmic); these included four oncogenes, telomerase (TERT), b-catenin (CTNNB1), PI3 kinase (PIK3CA), and the transcription factor NRF2 (NFE2L2), as well as one tumor suppressor, p53 (TP53). In addition, we included the oncogene MYC, which is under tight control in normal cells (Lowe et al., 2004) , but overexpressed in many cancer types, including HCC (Kalkat et al., 2017) . Lentiviral expression of the fluorescent reporter mCherry with the oncogenic drivers in different combinations revealed that the pool of three oncogenes, i.e. constitutively active b-catenin (CTNNB1 T41A ), MYC and TERT, together with TP53 inactivation by CRISPR-Cas9 (CMT+sgTP53) resulted in highly proliferative iHeps with apparently unlimited proliferative potential (> 50 passages over more than one year; Figure 2B) . Importantly, expression of the three oncogenes CTNNB1 T41A , MYC and TERT (CMT) alone also resulted in similar iHeps with long-term proliferative potential (Figure 2B) . By contrast, ectopic expression of these oncogenic drivers in HFs failed to yield transformed, proliferating fibroblasts, and rather resulted in cellular senescence and loss of the oncogene-transduced cells from the fibroblast population ( Figure 2B) . This is the first instance to our knowledge where HFs can be directly transformed using this minimal combination of defined factors, indicating that lineagespecific TFs are the missing link for human cellular transformation using oncogenic drivers.
Tumorigenic properties of the transformed iHeps
To test for the tumorigenicity of the proliferative iHeps, we performed xenograft experiments. Subcutaneous injection of the CMT+sgTP53 transformed iHeps, but not the control fibroblasts or iHeps with lineage-specific TFs alone, into nude mice resulted in tumor formation (Figures 3A and 3B) . The process was reproducible in subsequent experiments; in 6 addition, the effect was not specific to the fibroblast line used, as we also successfully reprogrammed another HF cell line (human fetal lung fibroblast) using the same lineagespecific TFs, and transformed it using the same set of oncogenic drivers. The xenograft tumors from the CMT+sgTP53 transformed iHeps derived from either fibroblast line can be detected by in vivo fluorescent imaging as early as 11-12 weeks (Figure 3B) . Importantly, the histology of CMT+sgTP53 tumors harvested at 20 weeks show highly malignant and proliferative HCC-like features (Figure 3C) . Similarly, the CMT-transformed iHeps without TP53 inactivation also resulted in tumor formation in nude mice 12 weeks post-injection ( Figure 3B) . These results demonstrate that both CMT and CMT+sgTP53 transformed iHeps are tumorigenic, and indicate that ectopic expression of defined lineage-specific TFs and oncogenes can reprogram and transform HFs into cells that can robustly initiate tumors in nude mice.
Cancer genomes harbor large-scale chromosomal aberrations and are characterized by aneuploidy (Palin et al., 2018; Taylor et al., 2018) . To understand the gross chromosomal aberrations in the transformed tumorigenic CMT and CMT+sgTP53 iHeps compared to normal HFs, we performed spectral karyotyping, which showed a normal diploid male (46, XY) in HFs and aneuploid karyotypes in transformed iHeps ( Figure 3D) . The aneuploid transformed iHeps with CMT+sgTP53 at early passage were characterized by two different populations with two distinct modal chromosome numbers (Figure 3D) . The modal chromosome number of the first population was 45, XY, whereas the second population was pseudotetraploid, with a modal chromosome number between 67-92, XY; this pseudotetraploid state was consistently observed in late passage transformed iHeps. The major chromosomal aberrations that were similar between the two populations were missing copies of chromosomes 4 and 13, a derivative of chromosome 19 containing a small portion of chromosome 3 [t3:19], an extra copy of Y and a loss of most of the p arm of chromosome 7 2. In comparison, the most common chromosomal aberrations reported in HCC are the gains of 1q (suggested target genes include WNT14, FASL) and 8q (MYC, WISP1) and the loss of 17p (TP53, HIC1), followed by losses of 4q (LEF1, CCNA) and 13q (RB1, BRCA3) (Cancer Genome Atlas Research Network, 2017; Moinzadeh et al., 2005) (Figure 3E ). The first three chromosomal aberrations are expected not to be present in our case, as the transformation protocol leads to activation of the Wnt pathway and MYC expression, and loss of p53.
Consistently with this, we did not observe lesions in 1q, 8q or 17p in our cells. However, other common aberrations found in HCC cells, loss of chromosomes 4 and 13 were detected in our transformed CMT+sgTP53 iHep cells (Figures 3D and 3E ). However, these chromosomal aberrations appeared not to be necessary for formation of tumors, as in the absence of targeted loss of p53 in CMT iHep cells, we did not observe these lesions ( Figure   3D ). However, both CMT+sgTP53 and CMT iHeps displayed pseudotetraploidy, similar to what is commonly observed in HCC (Figures 3D and 3E) . These results indicate that the transformed iHeps have similar chromosomal aberrations to those reported earlier in liver cancer, consistent with their identity as HCC-like cells.
Transformed iHeps show gene expression profile similar to liver cancer
To understand the gene expression dynamics and to map the early events of lineage conversion and oncogenic transformation, we performed single cell RNA-sequencing (scRNA-seq) of HFs and iHeps with or without oncogene transduction. The cells were clustered according to their expression profiles using Seurat ; a total of 15 separate clusters of cells were identified during the course of the transdifferentiation and reprogramming and visualized by t-distributed stochastic neighbour embedding (t-SNE) plots (van der Maaten and Hinton, 2008) (Figures 4A and 4B) . Importantly, the scRNA-seq indicated that the CMT-transformed iHeps are a clearly distinct population of cells compared to the iHeps, whereas CMT-transduced HFs are more similar to the control HFs (Figure 4B) .
To determine the trajectory of differentiation of the cells, we performed RNA velocity analysis (La Manno et al., 2018) , which determines the direction of differentiation of individual cells based on comparison of levels of spliced mRNAs (current state) with nascent unspliced mRNAs (representative of future state). This analysis confirmed that the cell populations analyzed were differentiating along the fibroblasts-iHep-transformed iHep axis ( Figure 4C ). We next identified marker genes for each cell cluster (see Methods). This analysis revealed that CMT-iHeps have a distinct gene expression signature and that they have lost the fibroblast gene expression program during the course of the reprogramming ( Figure S3A) . These results indicate that the iHep conversion and transformation have led to generation of liver-cell like transformed cells.
To further analyze gene expression changes during reprogramming and transformation, we performed pseudo-temporal ordering analysis of the scRNA-seq (see Methods). Consistently with the RNA velocity analysis, the pseudotime analysis showed transition from fibroblasts to iHeps and subsequently to CMT-transformed iHeps ( Figure   S3B ). Similarly, CMT-transduced HF cells were ordered across pseudo-temporal time line ( Figure S3B) . The scRNA-seq analyses allow detection of the precise early events that occur during iHep formation and the origin of HCC by mapping the gene expression changes in the cells across the pseudotime. Furthermore, analyzing the molecular changes upon CMTtransduction provided mechanistic understanding of why oncogenes fail to transform HFs without iHep conversion (Figure 4D) ; the pseudotime analysis of gene expression changes from CMT-transduced HFs at one and three weeks compared to control HFs was highly similar to the previously reported signature of cellular senescence (17 out of 18 genes; Marthandan et al., 2016) (Figure 4D) . The senescence signature was much weaker both during transdifferentiation of the iHeps and during their transformation ( Figure S3C) ; instead, during iHep differentiation, the expression of non-canonical Wnt pathway components, including Wnt5a ligand and the Frizzled 5 receptor, were upregulated ( Figure   4D ). During transformation, the exogenous CTNNB1 T41A activated the canonical Wnt pathway, suppressing expression of the non-canonical ligand Wnt5a. We also observe activation of the NOTCH pathway early during tumorigenesis; expression of NOTCH1, NOTCH3 and their ligand JAG1 (Figure 4D , top) are strongly upregulated, together with the canonical NOTCH target gene HES1 (Borggrefe and Oswald, 2009) and the liver specific target NR4A2 (Zhu et al., 2017) . These results are consistent with the proposed role of the NOTCH pathway in liver tumorigenesis (Villanueva et al., 2012; Zhu et al., 2017) . Thus, we show that CMT transduced HFs undergo senescence, whereas the proliferative phenotype of CMT-iHep cells is associated with gene expression changes in Wnt and NOTCH signaling pathways.
To determine whether the gene expression signatures observed in transformed iHeps were similar to those observed in human liver tumors, we compared the scRNA-seq results to the published liver cancer data sets (Cancer Genome Atlas Research Network, 2017).
Majority of the cases in TCGA HCC pan-cancer dataset show genetic alterations in CMT-iHep-specific marker genes (Figure S3A , 69% of 372 cancer cases) and the CMT-iHepspecific markers showed larger overlap with HCC when compared to cancers of pancreas and prostate, suggesting the specificity of this set of genes for liver tumorigenesis (Figure S3D) .
We also analyzed the expression of the CMT-iHep marker genes that show genetic alterations in TCGA liver cancer data across the pseudotime in our scRNA-seq data. The expression of this subset of the CMT-iHep marker genes was also clearly increased, lending further credence to the fact that upregulation of this set of genes is an early event in liver tumorigenesis ( Figure S3E ).
Direct conversion of human fibroblasts to liver cancer cells results in up-regulation of liver cancer markers
To determine the changes in gene expression and chromatin accessibility in the proliferative iHeps, we first performed bulk RNA-seq analysis from the tumorigenic CMT and CMT+sgTP53 iHeps that were used for the xenograft implantation, as well as cells derived from the resulting tumors. Importantly, the genes that were differentially expressed in both CMT-and CMT+sgTP53-transformed iHeps compared to fibroblasts showed a clear and significant positive enrichment for the previously reported "subclass 2" liver cancer signature (Hoshida et al., 2009) , associated with proliferation and activation of the MYC and AKT signaling pathways ( Figure 4E) . The effect was specific to liver cancer, as we did not observe significant enrichment of gene expression signatures of other cancer types ( Figure   S4 ). During the reprogramming, we observed a clear up-regulation of common liver marker genes such as ALB, APOA2, SERPINA1, and TF, and down-regulation of fibroblast markers such as MMP3, FGF7, THY1, and FAP, in proliferative and tumorigenic iHeps. Importantly, the xenograft tumor from the CMT+sgTP53 cells retained similar liver-specific gene expression profile ( Figure 5A) . We also detected a clear up-regulation of several liver cancer marker genes such as AFP, GPC3, SAA1, and VIL1 in transformed iHeps and in CMT+sgTP53 tumors compared to control fibroblasts ( Figure 5A) ; AFP was also found among the most enriched genes (Figure S5A ) in both CMT+sgTP53-and CMT-transformed iHeps. Furthermore, we observed a negative correlation between the CMT+sgTP53 and CMT iHep specific genes and the genes positively associated with liver cancer survival ( Figure   S5B ), lending further credence to liver cancer-identity of the CMT+sgTP53 and CMT transformed iHeps.
ATAC-seq analysis of the fibroblasts and CMT+sgTP53 cells revealed that the changes in marker gene expression were accompanied with robust changes in chromatin accessibility at the corresponding loci ( Figure 5B) . To assess chromatin accessibility and DNA methylation at a single-allele level, we performed NaNoMe-seq (see Methods), where accessible chromatin is methylated at GpC dinucleotides using the bacterial methylase M.CviPI (Kelly et al., 2012) . Sequencing of the genome of the treated cells using singlemolecule Nanopore sequencer then allows both detection of chromatin accessibility (based on the presence of methylated cytosines at GC dinucleotides) and DNA methylation at CG dinucleotides. This analysis confirmed the changes in DNA accessibility detected using ATAC-seq ( Figure 5C ). Changes in DNA methylation at promoters of the differentially expressed genes were relatively minor (Figure 5C ), suggesting that the mechanism of reprogramming does not critically depend on changes in CpG methylation at the marker loci.
Taken together, these results indicate that our novel cell transformation assay using lineagespecific TFs and cancer-specific oncogenes can reprogram fibroblasts to lineage-specific cancer that bears a gene expression signature similar to that observed in HCC.
Cellular lineage and the differentiated state of cells along the lineage are critical for tumorigenesis
To identify the necessary and sufficient factors that define lineage-specific cancer types we have here developed a novel cellular transformation protocol, and, for the first time, report direct conversion of HFs to liver cancer cells. First, lentiviral overexpression of three lineage-specific TFs reprograms HFs to iHeps, and subsequent ectopic expression of liver cancer-specific oncogenic factors transforms iHeps to a highly proliferative and tumorigenic phenotype with chromosomal aberrations and gene expression signature patterns similar to HCC. Importantly, lineage-conversion by specific TFs is required for the transformation process since the same oncogenic drivers alone do not transform HFs (Figure 6A ). After lineage conversion by the defined TFs, oncogenes alone (MYC, CTNNB1 and TERT) are sufficient to drive the transformation with or without inactivation of the tumor suppressor TP53. In contrast, oncogene transduction induces senescence in both HFs and in differentiated adult human hepatocytes (Figure 6A) . Interestingly, ectopic expression of TFs used for iHep conversion (HNF1A, HNF4A, and FOXA3) one week prior to oncogene transduction protects the hepatocytes from oncogene-induced senescence (Figure 6A) . These results show that fully differentiated hepatocytes are not susceptible for transformation by the liver-specific set of oncogenes, indicating that in addition to cellular lineage, also the differentiated state of cells along the lineage is critical for tumorigenesis. This finding is consistent with our experiments studying transformation in reprogrammed induced neurons (iNs). As these cells become terminally differentiated and post-mitotic immediately upon transdifferentiation, neither medulloblastoma nor neuroblastoma-specific oncogenes were able to make them re-enter the cell cycle (Figure 6A and Figure S6) . These results establish a paradigm for testing the tumorigenicity of combinations of cancer genes, and their interactions with cellular lineage and differentiated state (Figure 6B ). In addition, reprogramming normal cells to cancer cells allow "live" analysis of the early stages of the tumorigenic program, facilitating approaches towards early molecular detection and prevention of cancer.
DISCUSSION
In the past half-century, a very large number of genetic and genomic studies have been conducted using increasingly powerful technologies, resulting in identification of more than 250 genes that are recurrently mutated in cancer. However, in most cases, the evidence that the mutations in the genes actually cause cancer is correlative in nature, and requires 13 assumptions about background mutation frequency and rates of clonal selection in normal tissues (Martincorena et al., 2018) . Furthermore, cancer genes are known to act in combination, and determining candidate sets of genes that are sufficient to cause cancer using genetic data alone would require astronomical sample sizes. Mechanistic studies are thus critical for conclusively determining that a particular gene is essential for cancer formation, and for identification of sets of genes that are sufficient for tumorigenesis. In principle, individual driver genes and their combinations could be identified and validated using particular primary cell types. However, approaches using primary cells are severely limited by the fact that for most tissues, sufficient amounts of live human tissue material are hard to obtain. Furthermore, the cell type of origin for most cancer types is not known, and it is commonly assumed that tumors originate from rare and hard-to-isolate subpopulations of cells (e.g. stem cells, or transient progenitor cells in the case of pediatric tumors). Although some previous studies have reported oncogene combinations that can transform primary human cells (Drost et al., 2015; Matano et al., 2015; Park et al., 2018) , many primary cells may not be at the specific differentiated state that is required for transformation ( Figure 6B) .
For example, the combination of oncogenes required to transform cells to the most common prostate or lung cancer forms is not known. However, both primary prostate and lung epithelial cells can be transformed to small cell neuroendocrine carcinoma, suggesting that either a minority population of neuroendocrine cells are susceptible for transformation, or that both types of primary cells assume a neuroendocrine fate after transformation (Park et al., 2018) .
Our approach allows more precise control of cell identity and differentiation state, facilitating analysis of interactions between driver genes, cell lineage and cell state ( Figure   6B ). Our results using the novel cellular transformation assay show that HFs can be directly converted to lineage-specific cancer. Using this assay, we were able to determine the 14 minimum events necessary for making human liver cancer in culture. By using lineagespecific TFs to generate the cell type of interest for transformation studies, our molecular approach can be generalized for identifying minimal determinants of any cancer type, paving the way towards elucidating the exact molecular mechanisms by which specific combinations of mutations cause particular types of human cancer. BS performed the NaNoMe-seq and KP analyzed the data with inputs from SA and LA. AC and KZ performed bulk RNA-seq analysis with inputs from BS and PP. AR reviewed and analysed the immunohistochemistry slides, SH provided the bioinformatics support and inputs into the project. All authors contributed to the writing of the manuscript.
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METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jussi Taipale (ajt208@cam.ac.uk).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell lines used in this study include human foreskin fibroblasts (HFF, CCD-1112Sk) and human fetal lung (HFL) fibroblasts that were obtained from ATCC (#CRL-2429 and #CCL-153, respectively) and cultured in fibroblast medium (DMEM supplemented with 10% FBS and antibiotics, Thermo Fisher Scientific). Primary adult human hepatocytes (#HUCPI, batch HUM4122A, Lonza) were plated on type I collagen-coated 24-well plates in plating medium (MP100, Lonza) and maintained in hepatocyte growth medium (HCM, Lonza) as per vendor's instructions. In xenograft experiments, 6-week old immunodeficient BALB/c nude male mice (Scanbur) were used.
METHODS DETAILS
Plasmids and lentiviral production
Full-length coding sequences for the TFs and oncogenes were obtained from GenScript and cloned into the lentiviral expression vector pLenti6/V5-DEST using the to the guide sequences targeting the TP53 gene in the GeCKO library were ordered from IDT, annealed, and ligated into lentiGuide-Puro backbone (Shalem et al., 2014) . For virus production, the plasmids were co-transfected with the packaging plasmids psPAX2 and pMD2.G (Addgene #12260 and #12259, respectively) into 293FT cells (Thermo Fisher Scientific) with Lipofectamine 2000 (Thermo Fisher Scientific). Fresh culture medium was replenished on the following day, and the virus-containing medium was collected after 48 h.
The lentiviral stocks were concentrated using Lenti-X concentrator (Clontech) and stored as single-use aliquots.
Generation of iHeps
LentiCas9-Blast virus was transduced to early-passage human fibroblasts (MOI = 1) with 8 µg/ml polybrene. Blasticidin selection (4 µg/ml) was started two days after transduction and continued for two weeks. Early passage blasticidin-resistant cells were used (Huang et al., 2014) with MOI = 0.5 for each factor and 8 µg/ml polybrene (day 1). The medium was changed to fresh fibroblast medium containing βmercaptoethanol on day 2 and to a defined hepatocyte growth medium (HCM, Lonza) on day 3. On day 6, the cells were passaged on plates coated with type I collagen (Sigma) in several technical replicates, and thereafter, the HCM was replenished every two-three days.
Primary adult human hepatocytes (#HUCPI, batch HUM4122A, Lonza) were plated on type I collagen-coated 24-well plates in plating medium (MP100, Lonza) and maintained in hepatocyte growth medium (HCM, Lonza) as per vendor's instructions. One day after plating, cells were transduced either with TFs that were used for iHep conversion (FOXA3,   22 HNF4A, HNF1A, MOI = 0.5) or with CMT oncogenes (CTNNB1 T41A , MYC, TERT, MOI = 1) with 8 µg/ml polybrene in HCM medium. Fresh HCM medium was replenished on the following day and regularly thereafter. Seven days after iHep-TF transduction, these cells were transduced with CMT oncogenes as above. Beta-galactosidase staining for senescence analysis was performed three weeks after plating the cells.
Generation of HCC-like cells
The iHeps generated using the three TFs (FOXA3, HNF4A, HNF1A) were passaged on type I collagen-coated plates on day 19 after iHep induction (p2) in HCM and transduced with different combinations of lentiviral constructs encoding the oncogenes (CTNNB1 T41A , MYC, TERT, NFE2L2, PIK3CA E545K ) on day 21 (MOI = 1 for each factor with 8 µg/ml polybrene). For CMT+sgTP53 condition, the CMT oncogenes (CTNNB1 T41A , MYC and TERT) were transduced along with a pool of six sgRNAs targeting the TP53 gene. Fresh HCM was replenished on the day following the transduction, cells were maintained in HCM, and passaged when close to confluent. From fifth passaging onwards after oncogene induction, cells were maintained in HCM supplemented with 1% defined FBS (Thermo Fisher Scientific). For single-cell RNA-sequencing experiments, the iHeps were transduced with CMT oncogenes (MOI = 1 with 8 µg/ml polybrene) on day 8 with fresh HCM replenished on day 9, and the cells were harvested for single-cell RNA-sequencing at the indicated time points from replicate culture wells. In all experiments, viral construct for mCherry expression was co-transduced with the oncogenes. As controls, HFs were transduced with the same combination of oncogenes (CTNNB1 T41A , MYC, TERT, MOI = 1 for each factor with 8 µg/ml polybrene). Fresh medium was changed on the day following the transduction, and the cells were passaged regularly. Cells were harvested for scRNA-seq analysis one and three weeks after transduction, and used for beta-galactosidase staining three weeks after transduction.
Generation of induced neurons (iN)
HFs were plated on Matrigel-coated wells and transduced on the following day with tetracycline-inducible TF constructs for iN conversion (Ascl1, Brn2, Myt1l, NeuroD1, and Ngn2) with MOI = 0.3 for each factor and 8 µg/ml polybrene with co-transduction of lentiviral construct for EGFP; day 1). The medium was changed to fresh fibroblast medium containing β-mercaptoethanol on day 2. Doxycycline induction (2 ug/ml) was started on day 5, and the medium was replaced with defined N2B27 neuronal medium supplemented with small molecules (CHIR, SB431542, LDN, dcAMP, and Noggin) and doxycycline on day 6 and cells were maintained in the defined medium thereafter. At three weeks of iN conversion, cells were transduced with one of the two oncogene pools specific either for neuroblastoma (ALK R1275Q , MYCN, NRAS Q61R , PIK3CA E545K , BRAF V600E , PTPN11, PDGFRA, KIT, IDH1 R132H ) or for medulloblastoma (CTNNB1 T41A , NRAS Q61R , PIK3CA E545K , SMO W535L , H3F3A K28M , IDH1 R132H ) with MOI = 0.5 for each factor and 8 µg/ml polybrene in neuronal medium. Fresh neuronal medium was replaced on the following day, the cells were maintained in neuronal medium and followed for 10-20 weeks.
Xenografts 24
Oncogene-induced CMT and CMT+sgTP53 cells at p20 and control iHeps were harvested, 10 7 cells were resuspended in HCM supplemented with 1% defined FBS and mixed with equal volume of Matrigel (growth factor reduced basement membrane matrix, Corning #356231) and injected subcutaneously into the flank of a 6-week old immunodeficient BALB/c nude male mice (Scanbur). Similarly, 10 7 control fibroblasts were injected in equal volume of fibroblast medium and Matrigel. In vivo imaging of the tumors was performed for the mice under isoflurane anesthesia using the Lago system (Spectral Instruments Imaging). Photon counts from the mCherry were detected with fluorescence filters 570/630 nm and superimposed on a photographic image of the mice. Tumors were harvested 23-25 weeks after injection. All the experiments were performed according to the guidelines for animal experiments at the University of Helsinki and under license from appropriate Finnish Review Board for Animal Experiments.
SKY analysis
Spectral karyotype analysis was performed at Roswell Park Cancer Institute Pathology Resource Network. Cells were treated for 3 hours with 0.06 µg/ml of colcemid, harvested and fixed with 3:1 methanol and acetic acid. Metaphase spreads from fixed cells were hybridized with SKY probe (Applied Spectral Imaging) for 36 hours at 37 degrees Celsius. Slides were prepared for imaging using CAD antibody kit (Applied Spectral Imaging) and counterstained with DAPI. Twenty metaphase spreads for each cell line were captured and analyzed using HiSKY software (Applied Spectral Imaging).
RNA isolation, qPCR and bulk RNA-sequencing
Total RNA was isolated from the control fibroblasts, iHeps harvested at day 5 and at weeks two, three, and four, CMT and CMT+sgTP53 cells harvested at p20, and from tumor tissues stored in RNALater (Qiagen), using RNeasy Mini kit (Qiagen) with on-column DNase I treatment. For qRT-PCR analysis, cDNA synthesis from two biological replicates was performed using the Transcriptor High-fidelity cDNA synthesis kit (Roche) and realtime PCR using SYBR green (Roche) with primers specific for each transcript (GAPDH-FP 5'-GGCCTCCAAGGAGTAAGACC, GAPDH-RP 5'-AGGGGAGATTCAGTGTGGTG, ALB-FP 5'-GGATGAAGGGAAGGCTTCGT, ALB-RP 5'-GAAATCTCTGGCTCAGGCGA, TF-FP 5'-GGCCACTAAGTGCCAGAGTT, TF-RP 5'-ATCCAGTGTCACAGCATCCG, SERPINA1-FP 5'-CTGTCTCCTCAGCTTCAGGC, SERPINA1-RP 5'-CACGAGACAGAAGACGGCAT). The Ct values for the target genes were normalized to those of GAPDH, and the mean values of sample replicates were shown for different conditions at the indicated time points. RNA-sequencing was performed from three biological replicate samples for each condition, using 400 ng of total RNA from each sample for poly(A) mRNA capture followed by stranded mRNA-seq library construction using KAPA stranded mRNA-seq kit for Illumina (Roche) as per manufacturer's instruction.
Final libraries with different sample indices were pooled in equimolar ratios based on quantification using KAPA library quantification kit for Illumina platforms (Roche) and size analysis on Fragment Analyzer (AATI) and sequenced on HiSeq 4000 (Illumina).
For preprocessing and analysis of the RNA-Seq reads the SePIA pipeline (Icay et al., 2016 ) based on the Anduril framework (Ovaska et al., 2010) was used. Quality metrics from the raw reads were estimated with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and Trimmomatic (Bolger et al., 2014 ) clipped adaptors and low-quality bases. After trimming, reads shorter than 20 bp were discarded. Kallisto (v0.44.0) with Ensembl v85 (Zerbino et al., 2018) was used for quantification followed by tximport (Soneson et al., 2015) and DESeq2 (Love et al., 2014) (v1.18.1) for differential expression calculating log2(fold change) and standard error from 26 triplicate samples. Gene set enrichment analysis (Subramanian et al., 2005) Quality control was applied separately for iHep and HFL-CMT samples. iHeps with fewer than 50,000 mapped reads, or expressing fewer than 4000 genes or with greater than 6% UMI originating from mitochondrial genes were excluded, while for HFL-CMT samples, cells with fewer than 2500 genes or with greater than 10% UMI originating from mitochondrial genes were excluded. All genes that were not detected in at least 5 cells were discarded. From each sample, 500 cells were down-sampled for further analysis. The data was normalized and log-transformed using Seurat (version 3.0.2). A cell cycle phase-specific score was generated for each cell, across five phases (G1/S, S, G2/M, M and M/G1) based on Macosko et al. (Macosko et al., 2015) using averaged normalized expression levels of the markers for each phase. The cell cycle phase scores together with nUMI and percentage of UMIs mapping to mitochondrial genes per cell were regressed out using a negative binomial model. The graph-based method from Seurat was used to cluster the cells. The first 30 PCs were used in construction of SNN graph, and 15 clusters were detected with a resolution of 0.8. Markers specific to each cluster were identified using the "negbinom" model. Pseudotime trajectories were constructed with URD (Farrell et al., 2018) (version 1.0.2). The RNA velocity analysis was performed using velocyto (La Manno et al., 2018) (version 0.17).
Oil-Red-O-and PAS-staining and beta-galactosidase activity assay
Oil-Red-O and Periodic Acid-Schiff (PAS) staining were performed according to the manufacturer's recommendation (Sigma). Briefly, for Oil-Red-O-staining, cells were fixed with paraformaldehyde (4%) for 30 mins, washed with PBS, incubated with 60% isopropanol for 5 mins and Oil-Red-O working solution for 10 mins, and washed twice with 70% ethanol.
For PAS-staining, cells were fixed with alcoholic formalin (3.7%) for 1 min, incubated with PAS solution for 5 mins and Schiff's reagent for 15 mins with several washes with water between each step, and counter-stained with hematoxylin. Beta-galactosidase assay was performed using Senescence detection kit (Abcam) according to the manufacturer's protocol for fixation and staining (overnight).
Immunohistochemistry
Tumor tissues were collected from mice injected with CMT+sgTP53 cells and fixed in 4% paraformaldehyde at 4°C overnight, dehydrated and embedded in paraffin. Five-μm sections were stained with hematoxylin and eosin with Tissue-Tek DRS automated system at Tissue Preparation and Histochemistry Unit (University of Helsinki, Finland) using standard protocols. For Ki-67 detection, sections were dewaxed with xylene, rehydrated, boiled in 10 mM citrate buffer, and treated with 3% hydrogen peroxide for 5 min to block the endogenous peroxidase activity. Sections were incubated with Anti-Ki-67 antibody (sc-101861, SantaCruz) at 4°C overnight followed by 40 min incubation with Brightvision Poly-HRP-Anti Mouse staining reagent (ImmunoLogic). The immune complexes were visualized using DAB Quanto chromogen and substrate (ThermoFisher) and counterstained with hematoxylin.
The slides were dehydrated and mounted using Eukitt (Sigma).
ATAC-seq
Fibroblasts and CMT+sgTP53 cells (p20) were harvested and 50,000 cells for each condition were processed for ATAC-seq libraries using previously reported protocol (Corces et al., 2017) and sequenced PE 2x75 NextSeq 500 (Illumina). The quality metrics of the FASTQ files were checked using FASTQC and the adapters were removed using trim_galore. The reads were aligned to human genome (hg19) using BWA, and the duplicate reads and the mitochondrial reads were removed using PICARD. The filtered and aligned read files were used for peak calling using MACS2 and for visualizing the traces using the IGV genome browser. NaNoME-seq (NOME-seq using Nanopore sequencing)
To profile chromatin accessibility using GC methylase using NOME-seq protocol (Kelly et al., 2012) and to utilize the ability of Nanopore sequencing to detect CpG methylation without bisulfite conversion and PCR, we adapted the NOME-seq protocol for Nanopore sequencing on Promethion (NaNoME-seq). The nuclei isolation and treatment with GC methylase (M.CviPI) was performed as described earlier (Kelly et al., 2012) . The DNA was isolated from GC methylase treated nuclei by phenol chloroform followed by ethanol precipitation. The sequencing library for Promethion was prepared using the 1D genomic 29 DNA by ligation kit (SQK-LSK109) as per manufacturer's recommendation and we loaded 50 fmol of final adapter-ligated high molecular weight genomic DNA to the flow cells for sequencing. After sequencing and base calling, the Nanopore reads were aligned to GRCh37 reference genome with minimap2 (Li, 2018) . Nanopolish (Simpson et al., 2017) was modified to call methylation in GC context. In total, 11Gbp of aligned read data from PCR amplified and GC methylated sequencing run was used to learn emission model for methylated GC sites. The learning process followed https://github.com/jts/methylationanalysis/blob/master/pipeline.make with adjustments for using human genome data and minimap2. For nuclear extract NaNoMe samples, methylation status was separately called for GC and CG sites. Similar independent method was recently described in a preprint by Lee et al (https://www.biorxiv.org/content/10.1101/504993v2). Reads with consecutive stretch of at least 80 GC sites with at least 75% methylated were filtered out due to expected cell free DNA contamination during library preparation as in Shipony et al.
(https://www.biorxiv.org/content/10.1101/504662v1). The per site methylation levels in Figure 5C are mean smoothed with triangular kernel 5 sites wide. Fibroblast and CMT+sgTP53 NaNoMe analyses used 20.3Gbp and 24.8Gbp of aligned data, respectively.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq: For preprocessing and analysis of the reads: SePIA pipeline based on the Anduril framework, clipping adaptors and low-quality bases: Trimmomatic. Kallisto (v0.44.0) with Ensembl v85 for quantification followed by tximport and DESeq2 (v1.18.1) for differential expression. Gene set enrichment analysis using GSEAPY (version 0.9.8).
Single cell RNA-seq: Preprocessing, demultiplexing, alignment, filtering, barcode counting, and unique molecular identifier (UMI) counting: CellRanger. Normalization and logtransformation: Seurat (version 2.3.4), cell cycle phase-specific scoring based on Macosko et 30 al. using averaged normalized expression levels of the markers for each phase. The cell cycle phase scores together with nUMI and percentage of UMIs mapping to mitochondrial genes per cell were regressed out using a negative binomial model. The graph-based clustering using Seurat. Markers specific to each cluster were identified using the "negbinom" model. Pseudotime trajectories were constructed with URD (version 1.0.2). The RNA velocity analysis was performed using velocyto (version 0.17).
ATAC-seq: the adapters were removed using trim_galore, the reads were aligned to human genome (hg19) using BWA, and the duplicate reads and the mitochondrial reads were removed using PICARD. Peak calling using MACS2. NaNoMe-seq: Nanopore reads were aligned usingh minimap2. Nanopolish was used to call GC methylation. For nuclear extract NaNoMe samples, methylation status was separately called for GC and CG sites. Similar independent method was recently described in a preprint by Lee et al (https://www.biorxiv.org/content/10.1101/504993v2). Reads with consecutive stretch of at least 80 GC sites with at least 75% methylated were filtered out due to expected cell free DNA contamination during library preparation as in Shipony et al.
(https://www.biorxiv.org/content/10.1101/504662v1).
DATA AND CODE AVAILABILITY
All sequence data is available under ENA accession PRJEB31262.
